Sumitomo Mitsui Trust Group Inc. Lowers Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,980,601 shares of the company’s stock after selling 786,127 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 2.30% of Recursion Pharmaceuticals worth $60,709,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares in the last quarter. FMR LLC grew its position in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the period. Geode Capital Management LLC increased its stake in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Recursion Pharmaceuticals by 2.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock valued at $14,108,000 after acquiring an additional 43,078 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 3.5 %

NASDAQ:RXRX opened at $7.49 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market cap of $2.93 billion, a P/E ratio of -4.90 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The firm has a 50-day simple moving average of $7.15 and a two-hundred day simple moving average of $6.89.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th.

Insider Activity

In other news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the transaction, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.